Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, PeruArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] 진단, [키워드] administration ANCOVA anti-SARS-CoV-2 IgG antibody BBIBP-CorV BNT162b2 BNT162b2 vaccine booster conducted COVID-19 infection COVID-19 vaccine dose Elderly patient evaluated geometric geometric mean ratio HCW healthcare worker Heterologous heterologous vaccine homologous IgG IgG antibody IgG level immunized immunogenic immunogenicity increase in median mRNA vaccine National of BNT162b2 participant Pfizer produced prospective cohort study reactogenic reactogenicity regimen regressions Safe significantly Sinopharm two group vaccination Vaccine vaccine for COVID-19 was measured [DOI] 10.1371/journal.pone.0268419 PMC 바로가기
Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workersArticle Published on 2022-10-032022-11-15 Journal: Pathogens and disease [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] assays B-cell baseline booster booster vaccines cellular Cellular immune response convalescent convalescent individual Coronavirus-2 determine ELISA ELISPOT ELISpot IFN-γ release assay first dose Health care worker health care workers hospital humoral humoral immune responses Humoral immunity IFN-γ IgG level IgG responses immune individual individuals interferon-γ janssen mounted mRNA mRNA vaccine natural immunity Netherlands occurred offer pandemic Pfizer postvaccination receiving recipient responses SARS-CoV-2 serological seronegative seropositive severe disease spike-specific cellular immunity Support T-cell T-cell Response vaccination Vaccine variants of concern vector vaccine. Virus neutralization VNT waned [DOI] 10.1093/femspd/ftac035 PMC 바로가기
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literatureArticle Published on 2022-10-012022-11-15 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome Adults affected analysed antibody AstraZeneca attack available data AZD1222 blindness BNT162b2 booster vaccination Brain Brainstem Brainstem encephalitis Case report cerebrospinal fluid ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1-S CNS complete recovery coronavirus Coronavirus disease 2019 Coronavirus disease 2019 (COVID-2019) COVID-19 CSF detectable disease dysfunction Encephalitis epidemiological Escalation exceeded female first dose functional glycoprotein IgG1 immunization Immunoglobulin Immunotherapy laboratory feature Longitudinally extensive transverse myelitis (LETM) majority male median median age median interval MOG MOG antibodies (MOG-IgG) mRNA vaccine mRNA-1273 mRNA-1273. much lower Myelin Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM) Myelitis Neuromyelitis Optica Neuromyelitis optica spectrum disorders occur occurred Optic Optic neuritis Oxford paraplegia Patient patients patients with SARS-CoV-2 Pfizer phenotype plasma Postinfectious Postvaccinal predominant radiological remained required residual symptom SARS-CoV2 serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) severity steroid treatment therapy Treatment Treatment outcome vaccination Vaccine WCC white cell [DOI] 10.1007/s00415-022-11194-9 PMC 바로가기
Patients with previous immediate hypersensitivity reactions to polyethylene glycol can safely receive the BNT162b2 mRNA COVID-19 vaccineArticle Published on 2022-10-012022-11-15 Journal: Internal medicine journal [Category] 진단, [키워드] allergic anaphylaxis BNT162b2 mRNA Community COVID-19 COVID-19 vaccine doses eight Evidence first dose glycol hospital hypersensitivity hypersensitivity reaction Mild molecular weight New offered Patient Pfizer reaction receive receiving Record second dose thought Vaccine Vaccines [DOI] 10.1111/imj.15821 PMC 바로가기
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathiesArticle Published on 2022-10-012022-11-15 Journal: Muscle & nerve [Category] 진단, [키워드] Active disease ADE ADEs adverse event analyzed Autoimmune benefit BNT162b2 collected comparable COVID-19 COVID-19 vaccination dermatomyositis Descriptive statistics disease dose evaluate HCs healthy control higher risk Hydroxychloroquine IBM Immunoglobulin impacted inactive Inflammatory inflammatory disorder International interquartile range investigated IQR less lower risk Major median age multivariable Myopathy myositis nine Odds ratio outcome Patient Pfizer postvaccination Rash recipients reported rheumatology risk severe COVID-19 vaccination vaccination. Vaccine was performed [DOI] 10.1002/mus.27681 PMC 바로가기
Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic reviewReview article Published on 2022-10-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] 임상, [키워드] 95%CI Admission age association ChAdOx1 nCoV-19 vaccine Characteristics clinical Clinical characteristics COVID-19 COVID-19 vaccines database female Follow-up Google Scholar identify independent risk factor janssen male Moderna Neurological complication occurred Oxford-AstraZeneca Patient patients with COVID-19 Pfizer post-COVID-19 vaccination Prognosis Prognostic factor radiological radiological feature reported Result score searched second dose Sinopharm systematic review the vaccine Therapeutic strategies transverse myelitis vaccination Vaccine worse prognosis [DOI] 10.1016/j.msard.2022.104032 [Article Type] Review article
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjectsArticle Published on 2022-09-292022-11-15 Journal: PLoS ONE [Category] SARS, 변종, 진단, [키워드] antibodies antibody Antigen applied Characteristics Collecting COVID-19 defined determine Dilution dilutions dose doses help humoral Humoral immunity immune response Infection information intensity linear long-lasting MONITOR Pfizer Prevent profile protective immunity quantification quantitative assay RBD reactivity Reinfection Sample SARS-CoV-2 SARS-CoV-2 antigens serological serology test serum sample subject two group vaccination Vaccination strategies Vaccine variant Viral antigen was used were used [DOI] 10.1371/journal.pone.0274553 PMC 바로가기
Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 VaccineArticle Published on 2022-09-282022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 진단, [키워드] acute respiratory syndrome allergic allergic reaction anaphylaxis antibody antigenic target Control controls coronavirus coronavirus 2 coronavirus disease COVID-19 exhibiting full-length functional humoral Humoral immunity hypersensitivity IgG1 Immunoglobulin individual messenger Messenger RNA Moderna mounted mRNA mRNA COVID-19 vaccine occur Patient Pfizer produced profile reaction receptor recipients reduction in respiratory RNA SARS-CoV-2 significantly lower Symptom systems serology vaccination vaccination. Vaccine [DOI] 10.1093/infdis/jiac107 PMC 바로가기
Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled TrialArticle Published on 2022-09-162022-11-15 Journal: Nutrients [Category] SARS, 진단, [키워드] 25-hydroxyvitamin D 95% CI Acute respiratory infection adjusted hazard ratio antibody baseline blood sample BNT162b2 BNT162b2 Pfizer boost Breakthrough SARS-CoV-2 infection cellular response ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 Oxford–AstraZeneca circulating collected Concentration concentrations Controlled deficiency determine dose dried blood spot Effect Efficacy elevated Follow-up IFN-γ IgA IgG IgM influence interferon interferon gamma investigated mean difference neutralising antibody neutralising antibody titre of BNT162b2 offer participant Pfizer Protective randomised controlled randomised controlled trial reported response risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly supernatant titre titres vaccination venous Vitamin Vitamin D Vitamin D status vitamin D supplement Vitamin D supplementation vitamin D. Whole blood [DOI] 10.3390/nu14183821 PMC 바로가기
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and AdultsArticle Published on 2022-09-142022-11-15 Journal: Journal of Virology [Category] SARS, 변종, 진단, [키워드] Adolescent adolescents adolescents and adult adolescents and adults Adults age antibody Antibody binding antibody binding titers approved Beta binding binding antibody BNT162b2 BNT162b2 vaccine booster booster dose booster vaccination breadth changes in children circulating clinical trial Cohort Coverage COVID-19 Delta demonstrated dose drug Effectiveness Efficacy evaluate FDA food Gamma highlight Hospitalization humoral immune response lack less Loss magnitude mounted mRNA vaccine neutralization Neutralizing antibody response omicron Omicron (B.1.1.529) pandemic pediatric Pfizer Pfizer-BioNTech Pfizer-BioNTech (BNT162b2) plasma populations PROTECT reduction reported Research response responses against robust SARS-CoV-2 seasonal beta coronavirus the antibody response the SARS-CoV-2 the vaccine vaccination Vaccine vaccine-induced antibody response Vaccine-induced immunity variant variant of concerns (VOCs) variants viral variant Virus neutralization virus neutralization. virus spike protein VoC VOCs while wild-type SARS-CoV-2 [DOI] 10.1128/jvi.00582-22 PMC 바로가기